SeaStar Medical posted net Revenue of $0.6 million for the quarter ended June 30 2026, an 82 % rise from $0.3 million a year earlier, driven by expanded pediatric AKI sales. The growth offsets rising R&D and administrative costs, leaving a $3.7 million loss but leaving $7.0 million in cash to fund the pivotal adult trial and upcoming regulatory work.
Key Highlights
- QUELIMMUNE sales climbed 82 % to $0.6 million, pushing gross Margin to 91 % despite a modest margin decline.
- Research and development expenses more than doubled to $2.5 million as the NEUTRALIZE‑AKI trial enrolled 223 of 339 patients.
- Cash on hand fell to $7.0 million from $12.0 million, while net loss widened to $3.7 million ($0.91 per share).
The recent revenue boost stems from securing new contracts with three top‑rated children’s hospitals, which pushes the QUELIMMUNE customer roster up to twenty distinct institutions and deepens order depth across the network. By widening the client base, the company not only spreads fixed costs over a larger Volume but also reduces reliance on any single site, a defensive move that can smooth short‑term Earnings volatility. Gross margin slipped marginally to 91 % from 92 % in the prior year, a modest erosion that still underscores the high‑margin nature of the pediatric selective cytopheretic device (SCD) platform while hinting at emerging pricing pressure as volumes climb.
The modest margin dip reflects higher variable costs tied to scaling production and the incremental logistics of serving a broader hospital set. Although the top‑line lift improves the headline revenue profile, it concurrently sits against a widening net loss and a shrinking cash pile, signaling that the upside from pediatric sales is not yet sufficient to offset the expanding expense base. This mismatch sets the stage for a capital‑intensive rollout of the adult acute kidney injury (AKI) program, where larger scale and regulatory hurdles will Demand significant additional funding.
Investors must therefore weigh the durability of the pediatric growth against the looming cash requirements of the adult pipeline.
QUELIMMUNE REVENUE JUMPS
The company’s pediatric product line drove the headline revenue surge, with QUELIMMUNE sales rising from $0.3 million to $0.6 million. Adding three elite children’s hospitals to the customer roster increased order depth and diversified the revenue stream across more institutions. Gross margin for the quarter held near the high‑90s, at 91 %, confirming the cost‑efficient nature of the selective cytopheretic device (SCD) platform.
While the margin dip from 92 % reflects higher variable costs tied to scaling production, the overall profitability remains strong for a niche therapy. This revenue acceleration improves the top‑line profile but does not fully offset the expanding expense base, leaving investors to weigh growth against cash burn. The stronger sales foundation also positions the company to Leverage upcoming ICD‑10‑PCS codes for broader inpatient billing.
R&D AND G&A SPENDING RISE
Research and development outlays climbed to $2.5 million, double the $1.0 million recorded a year prior, driven primarily by clinical trial expenses and additional personnel. The NEUTRALIZE‑AKI key trial, evaluating SCD therapy in adult ICU patients, has enrolled 223 of the 339 target participants, with enrollment expected to finish by year‑end or early 2027. General and administrative costs rose to $1.8 million from $1.0 million, reflecting higher compensation, legal fees, and SEC‑related expenditures.
Despite the cost increase, other income turned positive at $0.1 million versus a $0.2 million expense a year earlier, thanks to reduced financing fees and higher interest earnings. The heightened spending underscores the company’s commitment to advancing its adult AKI pipeline, yet it intensifies the need for future cash generation or external financing. The trial’s progress could transform the cost profile if regulatory approval unlocks a larger market.
CASH POSITION AND LOSS IMPACT
The broader loss reported for the quarter is driven primarily by higher Research and Development outlays and elevated general and administrative spending, both of which are only partially offset by modest gains in other income. Cash reserves have contracted to $7.0 million from $12.0 million at the close of the prior year, a decline that directly reflects operating cash consumption and the need to fund ongoing trial activities. While the remaining cash balance remains sufficient to meet near‑term obligations, the observed Burn Rate raises concerns about the length of the company’s runway if additional Capital is not secured.
This tightening of Liquidity forces management to explore strategic financing options, ranging from Equity raises to Debt facilities, in order to sustain the adult AKI development program and avoid jeopardizing critical trial milestones. For investors, the shrinking cash cushion heightens the importance of monitoring liquidity trends and assessing the likelihood of successful capital raises. The interplay between cash consumption and upcoming regulatory events creates a nuanced risk–reward profile that will shape valuation considerations going forward.
NEXT CATALYST: ADULT TRIAL AND FDA PATHWAY
The NEUTRALIZE‑AKI trial is structured to enroll a total of 339 adult patients, with the remaining 116 participants expected to be recruited by the close of 2026 or in early 2027, underscoring the program’s near‑term momentum. In parallel, the introduction of new ICD‑10‑PCS codes for SCD therapy, effective on October 1 2026, will enable standardized inpatient billing and potentially broaden revenue streams beyond the pediatric niche. Together, these developments create a decisive regulatory inflection point that could shift the addressable market from a limited pediatric cohort to a substantially larger adult population.
The trial’s outcomes, combined with a forthcoming pre‑market approval (PMA) filing, represent a critical catalyst that could dramatically reshape the company’s financial trajectory and valuation. Successful results would not only validate the therapeutic concept in a high‑need adult setting but also unlock reimbursement pathways that were previously unavailable. Consequently, investors should watch the trial’s progress and the timing of the PMA filing closely, as these events are poised to drive both revenue growth and market perception.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...